Tom:
The guy has great taste. He looks askant (sp?) at the B.S. and embraces the good science. A nose for mixing science with business.
But how he can keep from exploding while listening to some of the bozo analysts that they interview, I have no concept. I have great respect for that talent. I'd draw and quarter them. Heck, I'm ready to draw and quarter ANYONE who says "it's sort of like a biotech". We have scientists busting their butts to provide needed therapies and diagnostics. Meanwhile, CNBC, our major opinion-setting medium, brings in analysts and managers that have brought you past failures, and those individuals cover their incompetence by condemning the sector. Then the CNBC fools not only buy into it, they frigging promote it!!
Wall Street is a bunch of back-scratching, self-serving manipulators. There is little accountability. Biotech analysts just screw up and screw up and screw up. Then they just move to another underwriter. For some reason, the names go on but the past analytical crap is forgiven. Why does this happen?
CNBC........ while most others (including me) were getting their tail fed to them in the sector 10/97 to 8/98, Vector 1, Peter Suzman and Jim Silverman were publicly spelling out, here at SI, a route to profit. Instead of your usual bozos, why don't you interview them?
Urrrrrrrrrggggggggggggghhhhhhhhhhhhhhhhh. Gotta find something to punch.
Geeeeze, great week. Great day! I've been riding near-the-money calls in all the right places. ;-)
Good weekend, all.
Rick |
